FDAnews
www.fdanews.com/articles/85126-fda-to-discuss-new-indication-for-exelon

FDA TO DISCUSS NEW INDICATION FOR EXELON

March 8, 2006

An FDA advisory panel plans to consider Novartis' Alzheimer's drug Exelon for an additional indication of treatment for mild-to-moderate dementia associated with Parkinson's disease.

The agency's Peripheral and Central Nervous System Drugs Advisory Committee has scheduled a May 17 meeting to discuss the firm's supplemental new drug application for Exelon (rivastigmine tartrate). The drug was approved in April 2000 for the treatment of mild-to-moderate Alzheimer's disease.

For more information, access http://www.fda.gov/oc/advisory/accalendar/2006/cder12543d051706.html (http://www.fda.gov/oc/advisory/accalendar/2006/cder12543d051706.html).